CSIMarket
 


Cellectar Biosciences Inc   (CLRB)
Other Ticker:  
 

Cellectar Biosciences Inc 's Working Capital Ratio

CLRB's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




CLRB Working Capital Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities Change 109.82 % 61.08 % -7.85 % 11.96 % -20.96 %
Y / Y Current Assets Change -54.68 % -46.34 % -42.29 % -36.88 % 109.02 %
Working Capital Ratio MRQ 2.95 4.63 6.96 9.49 13.64
Overall Ranking # # # # #
Seq. Current Liabilities Change 16.56 % 21.07 % 17.04 % 27.04 % -10.51 %
Seq. Current Assets Change -25.8 % -19.46 % -14.16 % -11.65 % -12.16 %



Working Capital Ratio third quarter 2022 Comment
Due to increase in Current Liabilities in the third quarter 2022, Working Capital Ratio fell to 2.95 above Cellectar Biosciences Inc average.

Within Major Pharmaceutical Preparations industry Cellectar Biosciences Inc booked the highest Working Capital Ratio than Cellectar Biosciences Inc in the third quarter 2022. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is CLRB most successful ?
Working Capital Ratio CLRB on the trailing twelve month basis
Working Capital Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Working Capital Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Cellectar Biosciences Inc 's Current Liabilities $ 6 Millions Visit CLRB's Balance sheet
Cellectar Biosciences Inc 's Current Assets $ 19 Millions Visit CLRB's Balance sheet
Source of CLRB's Sales Visit CLRB's Sales by Geography


Cumulative Cellectar Biosciences Inc 's Working Capital Ratio

CLRB's Working Capital Ratio for the trailling 12 Months

CLRB Working Capital Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Current Liabilities TTM Growth 109.82 % 61.08 % -7.85 % 11.96 % -20.96 %
Y / Y Current Assets TTM Growth -54.68 % -46.34 % -42.29 % -36.88 % 109.02 %
Working Capital Ratio TTM 5.55 7.98 10.58 11.83 13.6
Total Ranking TTM # 338 # 551 # 538 # 494 # 405
Seq. Current Liabilities TTM Growth 16.56 % 21.07 % 17.04 % 27.04 % -10.51 %
Seq. Current Assets TTM Growth -25.8 % -19.46 % -14.16 % -11.65 % -12.16 %


TTM Working Capital Ratio Comment
On the trailing twelve months basis Due to increase in Current Liabilities in the III. Quarter to $6.37 millions, average cumulative Working Capital Ratio decreased to 5.55 below the Cellectar Biosciences Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 117 other companies have achieved higher Working Capital Ratio than Cellectar Biosciences Inc . While overall ranking remained unchanged compare to previous quarter at no. 338.

Explain Working Capital Ratio
Where is CLRB most successful ?
Working Capital Ratio CLRB on the trailing twelve month basis

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 118
Healthcare Sector # 217
Within the Market # 338


TTM Working Capital Ratio Statistics
High Average Low
13.16 7.76 4.55
(Sep 30 2021)  




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2022 MRQ Current AssetsSep 30 2022 MRQ Current Liabilities
Uniqure N v   8.07 $ 464.577  Millions$ 57.540  Millions
Galecto Inc   8.04 $ 71.199  Millions$ 8.858  Millions
Zentalis Pharmaceuticals Inc   8.03 $ 433.890  Millions$ 54.061  Millions
Aldeyra Therapeutics Inc   7.89 $ 189.483  Millions$ 24.010  Millions
Tango Therapeutics Inc   7.83 $ 401.674  Millions$ 51.322  Millions
Zai Lab Limited  7.78 $ 1,209.831  Millions$ 155.548  Millions
Evoke Pharma Inc   7.63 $ 13.257  Millions$ 1.738  Millions
Maravai Lifesciences Holdings Inc   7.61 $ 835.526  Millions$ 109.833  Millions
Geovax Labs Inc   7.55 $ 36.137  Millions$ 4.789  Millions
Lexicon Pharmaceuticals Inc   7.54 $ 139.063  Millions$ 18.445  Millions
Protagonist Therapeutics inc   7.53 $ 276.617  Millions$ 36.754  Millions
Immunic Inc   7.53 $ 86.649  Millions$ 11.514  Millions
Monopar Therapeutics Inc   7.51 $ 14.372  Millions$ 1.914  Millions
Assembly Biosciences Inc   7.44 $ 115.078  Millions$ 15.461  Millions
Roivant Sciences Ltd   7.43 $ 1,714.861  Millions$ 230.744  Millions
Xencor Inc  7.42 $ 667.998  Millions$ 90.032  Millions
Scynexis Inc   7.40 $ 103.565  Millions$ 13.995  Millions
Compass Pathways Plc  7.40 $ 218.451  Millions$ 29.533  Millions
Amarin Corp Plcuk  7.37 $ 686.520  Millions$ 93.157  Millions
Omeros Corporation  7.30 $ 288.545  Millions$ 39.514  Millions
Cns Pharmaceuticals Inc   7.26 $ 9.035  Millions$ 1.244  Millions
Bolt Biotherapeutics Inc   7.23 $ 174.826  Millions$ 24.174  Millions
Apellis Pharmaceuticals Inc   7.21 $ 831.937  Millions$ 115.446  Millions
Rain Therapeutics inc   7.20 $ 93.745  Millions$ 13.013  Millions
Siga Technologies Inc  7.17 $ 196.901  Millions$ 27.456  Millions
Nektar Therapeutics  7.14 $ 599.483  Millions$ 83.989  Millions
Cara Therapeutics inc   7.10 $ 186.780  Millions$ 26.316  Millions
Leap Therapeutics inc   7.06 $ 79.938  Millions$ 11.318  Millions
Phio Pharmaceuticals Corp   7.01 $ 15.377  Millions$ 2.194  Millions
Blueprint Medicines Corporation  6.99 $ 1,227.665  Millions$ 175.510  Millions

Date modified: 2022-11-06T02:10:30+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HGEN's Profile

Stock Price

HGEN's Financials

Business Description

Fundamentals

Charts & Quotes

HGEN's News

Suppliers

HGEN's Competitors

Customers & Markets

Economic Indicators

HGEN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071